

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Joseph SCHLESSINGER et al.  
Title: PYK2 AND INFLAMMATION  
Prior Appl. No.: 09/476,484  
Prior Appl. Filing Date: December 30, 1999  
Examiner: Unassigned  
Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/476,484, filed 12/30/1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date 2/27/04


FOLEY & LARDNER

Customer Number: 22428

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted,

By 

Beth A. Burrous

Attorney for Applicant

Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	1	<b>of</b>	24	<b>Attorney Docket Number</b>	034536-1246

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	3,691,016		PATEL	09-12-1972	
	A2	3,969,287		JAWOREK et al.	07-13-1976	
	A3	4,195,128		HILDEBRAND et al.	03-25-1980	
	A4	4,215,051		SCHROEDER et al.	07-29-1980	
	A5	4,229,537		HODGINS et al.	10-21-1980	
	A6	4,247,642		HIROHARA et al.	01-27-1981	
	A7	4,330,440		AYERS et al.	05-18-1982	
	A8	4,343,940		KREIGHBAUM et al.	08-10-1982	
	A9	4,376,110		DAVID et al.	03-08-1983	
	A10	4,444,752		PRUDDEN	04-24-1984	
	A11	4,757,072		KABBE et al.	07-12-1988	
	A12	4,945,050		SANFORD et al.	07-31-1990	
	A13	4,946,778		LADNER et al.	08-07-1990	
	A14	5,084,462	A	ACKERMAN et al.	01-28-1992	
	A15	5,242,932	A	GANDY et al.	09-07-1993	
	A16	5,296,353	A	OCHOA et al.	03-22-1994	
	A17	4,447,608		JONES et al.	05-08-1994	
	A18	5,316,553	A	KAUL et al.	05-31-1994	
	A19	5,580,882	A	ABRAMSKY et al.	12-03-1996	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
				<b>Attorney Docket Number</b>	034536-1246
<b>Sheet</b>	2	<b>of</b>	24		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A20	5,714,493	A	MYERS et al.	02-03-1998	
	A21	5,731,343	A	FENG et al.	03-24-1998	
	A22	5,804,396	A	PLOWMAN	09-08-1998	
	A23	5,834,504	A	TANG et al.	11-10-1998	
	A24	5,837,524	A	SCHLESSINGER et al.	11-17-1998	
	A25	5,837,815	A	LEV et al.	11-17-1998	
	A26	5,849,742	A	APP et al.	12-15-1998	
	A27	5,854,285	A	SRIRAM et al.	12-29-1998	
	A28	5,856,331	A	BURSTEN et al.	01-05-1999	
	A29	5,880,141	A	TANG et al.	03-09-1999	
	A30	5,932,573	A	YUEN	08-03-1999	
	A31	5,972,598	A	CHAUDHARY et al.	10-26-1999	
	A32	5,981,523	A	PANETTA et al.	11-09-1999	
	A33	5,985,926	A	LEUNG et al.	11-16-1999	
	A34	6,015,812	A	FERRARI et al.	01-18-2000	
	A35	6,077,851	A	BJORK et al.	06-20-2000	
	A36	6,121,287	A	BJORK et al.	09-19-2000	
	A37	6,143,764	A	KUBO et al.	11-07-2000	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
				<b>Attorney Docket Number</b>	034536-1246
<b>Sheet</b>	3	<b>of</b>	24		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A38	6,147,106	A	TANG et al.	11-14-2000	
	A39	6,214,873	B1	ADACHI et al.	04-10-2001	
	A40	6,235,769	B1	CLARY	05-22-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A41	GB	2 202 145	A	FISONS PLC	09-21-1988		
	A42	EP	0 516 297	A1	IMPERIAL CHEMICAL	10-30-1996		
	A43	EP	0 520 722	B1	ZENECA LIMITED	12-27-1996		
	A44	EP	0 562 734	B1	ZENECA LIMITED	12-20-1995		
	A45	WO	93/09236	A1	BAYLOR COLLEGE OF MEDICINE	05-13-1993		
	A46	WO	93/23569	A1	RIBOZYME PHARMACEUTICALS, INC.	11-25-1993		
	A47	WO	96/18738	A2	SUGEN, INC.	06-20-1996		
	A48	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
	A49	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
	A50	WO	98/16639	A1	SUGEN, INC. et al.	04-23-1998		
	A51	WO	98/26054	A2	SUGEN, INC. et al.	06-18-1998		
	A52	WO	98/35056	A1	MERK & CO., INC.	08-13-1998		

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
-	A53	AARONSON	"Growth Factors and Cancer," <i>Science</i> , 254:1146-1153 (1991)		
-	A54	ABE et al.	"Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Inositol Potosphate/Ca <sup>2+</sup> Signal," <i>J. Biol. Chem.</i> , 267(19):13361-13368 (1992), © The American Society for Biochemistry and Molecular Biology, Inc., USA		
-	A55	ADELMAN et al.	"In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," <i>DNA</i> , 2(3):183-193 (1983), Mary Ann Liebert, Inc., Publishers		
	A56	ALLEN et al.	"Modulation of CD4 by suramin" <i>Clin. Exp. Immunol.</i> , 91:141-146 (1991)		
	A57	ANAFI et al.	"Tyrphostin-Induced Inhibition of p210bcr-abl Tyrosine Kinase Activity Induces K562 to Differentiate," <i>Blood</i> , 82(12):3524-3529, December 15, 1993, © The American Society of Hematology, USA		
	A58	ANDRADE et al.	"A G Protein Couples Serotonin and GABA <sub>B</sub> Receptors to the Same Channels in Hippocampus," <i>Science</i> , 234:1261-1265 (1986)		
	A59	ANOUTI et al.	"Tremor Disorders: Diagnosis and Management" <i>Western J. Medicine</i> , 162(6):510-513 June 1995		
	A60	ARONHEIM et al.	"Membrane Targeting of the Nucleotide Exchange Factor Sos is Sufficient for Activating the Ras Signaling Pathway," <i>Cell</i> , 78:949-961, September 23, 1994, © Cell Press		
	A61	AVRAHAM et al.	"Identification and Characterization of a Novel Related Adhesion Focal Tyrosine Kinase (RAFTK) from Megakaryocytes and Brain," <i>J. Biol. Chem.</i> , 270:27742-27751 (1995)		
	A62	BAKER et al.	"Induction of Acetylcholine Receptor Clustering By Native Polystyrene Beads: Implication of an Endogenous Muscle-Derived Signaling System," <i>J. Cell Science</i> , 102:543-555 (1992), © The Company of Biologists Limited, Great Britain		
	A63	BARKER et al.	"In Vitro Activity of Non-Glutamate Containing Quinazoline-Based Thymidylate Synthase Inhibitors" <i>Proc. Am. Assoc. Cancer Res.</i> , 32:327 No. 1939, March 1991		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A64	BAUDY	"Agents for the Treatment of Neurodegenerative Diseases: Part 2," <i>Exp. Opin. Ther. Patents</i> , 4(4):343-378, (1994), © Ashley Publications ISSN 0962-2594		
	A65	BAYER et al.	"The Avidin-Biotin Complex in Affinity Cytochemistry," <i>Methods in Enzymology</i> , 62: 308-319 (1979), © Academic Press, Inc.		
	A66	BENOIST et al.	"In Vivo Sequence Requirements of the SV40 Early Promoter Region," <i>Nature</i> , 290:304-310, March 26, 1981		
	A67	BERTINO	"Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture" <i>Cancer Res.</i> , 39:293-304, February 1979		
	A68	BILDER et al.	"Tyrphostins inhibit PDGF-induced DNA Synthesis and Associated Early Events in Smooth Muscle Cells," <i>Am. J. Physiol.</i> , 260:C721-C730 (1991), © American Physiological Society		
	A69	BIRD et al.	"Single-Chain Antigen-Binding Proteins," <i>Science</i> , 242: 423-426, October 21, 1988		
	A70	BIRNSTIEL et al.	"Adenosine-Mediated Synaptic Inhibition: Partial Blockade by Barium Does Not Prevent Anti-Epileptiform Activity," <i>Synapse</i> , 11:191-196 (1992), © Wiley-Liss, Inc.		
	A71	BITTER et al.	"Expression and Secretion Vectors for Yeast," <i>Methods in Enzym.</i> 153:516-544 (1987), © Academic Press, Inc.		
	A72	BOLLON et al.	"DNA Transformation Efficiency of Various Bacterial and Yeast Host-Vector Systems," <i>J. Clin. Hematology and Oncology</i> , 10(2, 3):39-48, April -July 1980		
	A73	BORK	"Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Res.</i> , 10:398-400 (2000), © Cold Spring Harbor Laboratory		
	A74	BOTSTEIN et al.	"Making Mutations <i>in vitro</i> and Putting Them Back into Yeast," <i>Miami Winter Symposia – From Gene to Protein: Translation into Biotechnology</i> , eds. Ahmad et al., Academic Press, 19 265-274 (1982), © Academic Press		
	A75	BOWIE et al.	"Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310, March 16, 1990		
	A76	BRINSTER et al.	"Factors Affecting the Efficiency of Introducing Foreign DNA into Mice by Microinjecting Eggs," <i>Proc. Natl. Acad. Sci. USA</i> , 82:4438-4442, July 1985		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Prior Application Number</b>	09/476,484
		<b>Prior Appl. Filing Date</b>	12/30/99
		<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-1246
Sheet	6	of	24

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A77	BROACH	"The Yeast Plasmid 2 $\mu$ Circle," <i>Cell</i> , 28:203-204, February 1982, © MIT	
	A78	BROACH	"The Yeast Plasmid 2 $\mu$ Circle," in <i>The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance</i> , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 445-470 (1981)	
	A79	BROWN et al.	"Ionic Channels and Their Regulation by G Protein Subunits," <i>Ann. Rev. Physiol.</i> , 52:197-213 (1990), © Annual Reviews Inc.	
	A80	BRUNTON et al.	"Anti-Tumour Activity of Novel Tryphostins in Breast Cancer Cells." <i>Proceedings of the Am. Assoc. for Cancer Res.</i> , 33:558 (#3335), March 1992	
	A81	BRYCKAERT et al.	"Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," <i>Exp. Cell Research</i> , 199:255-261 (1992), © Academic Press, Inc.	
	A82	BULLOCK et al. (Eds.)	<i>Techniques in Immunocytochemistry</i> , Vols. 1, 2 and 3; TABLE OF CONTENTS ONLY, © Academic Press, Inc.	
	A83	BURGESS et al.	"Possible dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 From Its Receptor-Binding Activities By Site-Directed Mutagenesis of A Single Lysine Residue," <i>J. Cell Biol.</i> , 11:2129-2138 (1990), © The Rockefeller University Press	
	A84	BURKE et al.	"Arylamides of Hydroxylated Isoquinolines As Protein-Tyrosine Kinase Inhibitors" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2(12):1771-1774 (1992), © Pergamon Press Ltd., Great Britain	
	A85	BURKE et al.	"Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56 <sup>lck</sup> " <i>J. of Medicinal Chemistry</i> , 36(4):425-432, February 19, 1983, © American Chemical Society	
	A86	CAMPBELL	"Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas," <i>Laboratory Techniques in Biochemistry and Molecular Biology</i> , (TABLE OF CONTENTS ONLY), Vol. 13, © Elsevier Science Publishers, Amsterdam, The Netherlands, 1984	
	A87	CANTRELL	"G proteins in Lymphocyte Signalling," <i>Current Opinion in Immunology</i> , 6:380-384 (1994), © Current Biology Ltd.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Prior Application Number</b>	09/476,484
		<b>Prior Appl. Filing Date</b>	12/30/99
		<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-1246
Sheet	7	of	24

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A88	CAPECCHI	"Altering the Genome by Homologous Recombination," <i>Science</i> , 244:1288-1292, June 16, 1989	
	A89	CARMELIET	"Ion Channel Agonists: Expectations for Therapy." <i>Eur. Heart J.</i> , 12:30-37 (1991)	
	A90	CENATIEMPO	"Prokaryotic Gene Expression <i>In Vitro</i> : Transcription-Translation Coupled Systems," <i>Biochimie</i> , 68:505-515 (1986), © Societe de Chimie biologique/Elsevier, Paris	
	A91	CHATER et al.	"Streptomyces ØC31-Like Phages: Cloning Vectors, Genome Changes and Host Ranges," <i>Sixth International Symposium on Actinomycetes Biology</i> , eds. Szabe et al., Akademiai Kiado, Budapest, Hungary, 45-52 (1985)	
	A92	CHEN et al.	"High-Efficiency Transformation of Mammalian Cells by Plasmid DNA," <i>Mol. and Cell. Biol.</i> , 7(8):2745-2752, August 1987, © American Society for Microbiology	
	A93	CHEN et al.	"Shc Adaptor Proteins Are Key Transducers of Mitogenic Signaling Mediated By The G Protein-Coupled Thrombin Receptor," <i>EMBO Journal</i> , 15(5):1037-1044 (1996), © Oxford University Press	
	A94	CHOMCZYNSKI et al.	"Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," <i>Analytical Biochemistry</i> , 162:156-159 (1987), © Academic Press	
	A95	CHOWDHURY et al.	"Long-Term Improvement of Hypercholesterolemia After <i>Ex Vivo</i> Gene Therapy in LDLR-Deficient Rabbits," <i>Science</i> , 254:-1802-1805, December 20, 1991	
	A96	CHU et al.	"Electroporation for the efficient transfection of mammalian cells with DNA," <i>Nucleic Acids Res.</i> , 15(3):1311-1326 (1987), © IRL Press Limited, Oxford, England	
	A97	COBB et al.	"Stable Association of pp60 <sup>src</sup> and pp59 <sup>lyn</sup> with the Focal Adhesion-Associated Protein Tyrosine Kinase, pp125 <sup>FAK</sup> ," <i>Mol. and Cell. Biol.</i> , 14(1):147-155, January 1994, © American Society for Microbiology	
	A98	COLBÈRE-GARARPIN et al.	"A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells," <i>J. Mol. Biol.</i> , 150:1-14 (1981), © Academic Press, Inc. (London) Ltd.	
	A99	COLE et al.	"The EBV-Hybridoma Technique and its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , 77-96 (1985), Eds. Reisfeld et al., © Alan R. Liss, Inc., New York	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Prior Application Number</b>	09/476,484
		<b>Prior Appl. Filing Date</b>	12/30/99
		<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-1246
Sheet	8	of	24

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A100	COLEMAN et al. "Protection Against Dendrotoxin-Induced Clonic Seizures in Mice By Anticonvulsant Drugs," <i>Brain Res.</i> , 575:138-142 (1992), © Elsevier	
	A101	COTE et al. "Generation of Human Monoclonal Antibodies Reactive With Cellular Antigens," <i>Proc. Natl. Acad. Sci. USA</i> 80:2026-2030 (1983)	
	A102	CREIGHTON, T. <i>Proteins: Structures and Molecular Principles</i> , W.H. Freeman and Co., New York, 79-86 (1983)	
	A103	CRISTIANO et al. "Hepatic Gene Therapy: Adenovirus Enhancement of Receptor-Mediated Gene Delivery and Expression in Primary Hepatocytes," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2122-2126, March 1993	
	A104	CROMAKALIM "Antihypertensive Potassium Channel Activator Antiallergic/Antiasthmatic," <i>Drugs of the Future</i> , 17(3):237-239, March 1992	
	A105	CURIEL et al. "Adenovirus Enhancement of Transferrin-Polylysine-Mediated Gene Delivery," <i>Proc. Nat. Acad. Sci. USA</i> , 88:8850-8854, October 1991	
	A106	CURIEL et al. "Gene Transfer to Respiratory Epithelial Cells via the Receptor-mediated Endocytosis Pathway," <i>Am. J. Respir. Cell. Mol. Biol.</i> , 6:247-252 (1992)	
	A107	CURTIN et al. "Inhibition of The Growth of Human Hepatocellular Carcinoma <i>In Vitro</i> And In Athymic Mice By A Quinazoline Inhibitor of Thymidylate Synthase, CB3717," <i>Br. J. Cancer</i> , 53:361-368 (1986), © The Macmillan Press Ltd.	
	A108	DASHEIFF "A New Method of Monitoring Membrane Potential In Rat Hippocampal Slices Using Cyanine Voltage-Sensitive Dyes," <i>J. of Neuroscience Methods</i> , 13:199-212 (1985), © Elsevier	
	A109	DAUB et al. "Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors," <i>Nature</i> 379:557-560, February 8, 1996	
	A110	DIKIC et al. "A Role For PYK2 And Src In Linking G-Protein-Coupled Receptors With MAP Kinase Activation," <i>Nature</i> , 383: 547-560 (1996)	
	A111	DOLLE et al. "5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a Potent and Selective Inhibitor of Human Vascular $\beta$ -Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase" <i>J. Med. Chem.</i> , 37(17):2627-2629 (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	034536-1246
Sheet	9	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A112	DOLPHIN	"G Protein Modulation of Calcium Currents in Neurons," <i>Ann. Rev. Physiol.</i> , 52:243-55 (1990), © Annual Reviews Inc.	
	A113	DOMCHEK et al.	"Inhibition of SH2 Domain/Phosphoprotein Association by a Nonhydrolyzable Phosphonopeptide," <i>Biochemistry</i> , 31(41):9865-9870 (1992), © American Chemical Society	
	A114	DONG et al.	"Activation of Tumoricidal Properties In Macrophages By Lipopolysaccharide Requires Protein-Tyrosine Kinase Activity" <i>Journal of Leukocyte Biology</i> , 53:53-60, January 1993	
	A115	DONG et al.	"Protein Tyrosine Kinase Inhibitors Decrease Induction of Nitric Oxide Synthase Activity in Lipopolysaccharide-Responsive and Lipopolysaccharide-Nonresponsive Murine Macrophages" <i>J. Immunology</i> , 151(5):2717-2724, September 1, 1993, © The American Association of Immunologists, USA	
	A116	DONOVAN	"Thrombin-induced protection and apoptossie in astrocytes and neurons: signal transduction pathways and regulation by protease nexin-1," <i>Dissertation abstracts International</i> , 1997, p. 4072, Vol. 58, No. 08-B, abstract only	
	A117	DREBORG et al.	"Ch. 10 – The Chemistry and Standardization of Allergens," <i>Handbook of Experimental Immunology – Volume 1: Immunochemistry</i> , 4 <sup>th</sup> Ed., Eds. Weir et al., Blackwell Scientific Publications, Oxford, England, 10.1-10.28 (1986), Blackwell Scientific Publications	
	A118	ENGVALL et al.	"Enzyme-Linked Immunosorbent Assay, ELISA. III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen-Coated Tubes," <i>J. Immunology</i> , 109(1):129-135, July 1972, © The Williams & Wilkins Co.	
	A119	EZOE et al.	"PTK1, A Novel Protein Kinase Required For Proliferation of Human Melanocytes," <i>Oncogene</i> , 9:935-938 (1994), © Macmillan Press Ltd.	
	A120	FANTL et al.	"Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <i>Cell</i> , 69:413-423, May 1, 1992, © Cell Press	
	A121	FELDER et al.	"SH2 Domains Exhibit High-Affinity Binding to Tyrosine-Phosphorylated Peptides Yet Also Exhibit Rapid Dissociation and Exchange," <i>Mol. and Cell. Biol.</i> , 13(3):1449-1455 March 1993, © American Society for Microbiology	
	A122	FELGNER et al.	"Cationic Liposome-Mediated Transfection," <i>Nature</i> , 337:387-388, January 26, 1989	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	10	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A123	FELGNER et al.	"Lipofection: A Highly Efficient, Lipid-mediated DNA-transfection Procedure," <i>Proc. Natl. Acad. Sci. USA</i> , 84:7413-7417, November 1987		
	A124	FELSCH et al.	"Activation of Protein Tyrosine Kinase PYK2 By The M1 Muscarinic Acetylcholine Receptor" <i>PNAS</i> , 95:5051-5056, April 1998		
	A125	FERNANDES et al.	"Biochemical and Antitumor Effects of 5,8-Dideazaisopterylglytamate, a Unique Quinazoline Inhibitor of Thymidylate Synthase" <i>Cancer Res.</i> , 43:1117-1123, March 1983		
	A126	FERRARI et al.	"An <i>in Vivo</i> Model of Somatic Cell Gene Therapy for Human Severe Combined Immunodeficiency," <i>Science</i> , 251:1363-1366, March 15, 1991		
	A127	FERRIS et al.	"Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <i>J. Org. Chem.</i> , 44(2):173-178 (1979), © American Chemical Society		
	A128	FINGL et al.	"Section I, Introduction, Chapter 1, General Principles," <i>The Pharmacological Basis of Therapeutics</i> , 5 <sup>th</sup> Ed., Eds. Goodman et al., MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975)		
	A129	FISCHER and SCHONBRUNN	"Bombesin Receptor is Coupled to a Guanine Nucleotide-binding Protein Which is Insensitive to Pertussis and Cholera Toxins," <i>J. Biol. Chem.</i> , 263(6):2808-2816, February 25, 1988, © Society for Biochemistry and Molecular Biology, Inc., USA		
	A130	FISCHER et al.	"Protein Tyrosine Phosphatases: A Diverse Family of Intracellular and Transmembrane Enzymes," <i>Science</i> , 253:401-406, July 26, 1991		
	A131	FISCHER et al.	"Frontiers of Clinical Neuroscience, Volume 11: Neurotransmitters and Epilepsy," Wiley-Liss, New York (TABLE OF CONTENTS ONLY)		
	A132	FRUCHT et al.	"Characterization of Functional Receptors for Gastrointestinal Hormones on Human Colon Cancer Cells," <i>Cancer Research</i> , 52:1114-1122, March 1, 1992		
	A133	FRY et al.	"A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>Science</i> , 265:1093-1095, August 19, 1994		
	A134	FRY et al.	"New Insights Into Protein-Tyrosine Kinase Receptor Signaling Complexes," <i>Protein Science</i> , 2:1785-1797 (1993), Cambridge University Press, USA, © The Protein Society		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	034536-1246
Sheet	11	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A135	GAZIT et al.	"Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <i>J. Med. Chem.</i> , 32(10):2344-2352 (1989)		
	A136	GAZIT et al.	"Tyrphostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <i>J. Med. Chem.</i> , 34(6):1896-1907 (1991)		
	A137	GAZIT et al.	"Tyrphostins. 3. Structure-Activity Relationship Studies of a $\alpha$ -Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins," <i>J. Med. Chem.</i> , 36(23):3556-3564 (1993)		
	A138	GEHLERT et al.	"ATP Sensitive Potassium Channels: Potential Drug Targets in Neuropsychopharmacology," <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> , 18:1093-1102 (1994)		
	A139	GILLIES et al.	"Antigen Binding And Biological Activities of Engineered Mutant Chimeric Antibodies With Human Tumor Specificities," <i>Human Antibodies and Hybridomas</i> , 1: 47-54 (1990)		
	A140	GILMAN et al.	"Isolation of Sigma-28-Specific Promoters From <i>Bacillus Subtilis</i> DNA," <i>Gene</i> , 32:11-20 (1984), Elsevier		
	A141	GILMAN	"G Proteins: Transducers of Receptor-Generated Signals," <i>Ann. Rev. Biochem.</i> , 56:615-49 (1987), © Annual Reviews Inc.		
	A142	GISHIZKY et al.	"Mutant Forms of Growth Factor-Binding Protein-2 Reverse BCR-ABL-Induced Transformation," <i>Proc. Natl. Acad. Sci. USA</i> , 92:10889-10893 (1995)		
	A143	GLASER et al.	<u>Biochemical Pharmacology</u> , February 9, 1993, pp. 711-721, Vol. 45, No. 3		
	A144	GLICK et al.	"Factors Affecting The Expression of Foreign Proteins In <i>Escherichia Coli</i> ," <i>J. Industrial Microbiology</i> , 1:277-282 (1987), Elsevier		
	A145	GODING	"Conjugation of Antibodies with Fluorochromes: Modifications to the Standard Methods," <i>J. Immunological Methods</i> , 13: 215-226 (1976), © Elsevier/North-Holland Biomedical Press		
	A146	GOLD et al.	"Translational Initiation in Prokaryotes," <i>Ann. Rev. Microbiol.</i> , 35:365-403 (1981), © Annual Reviews Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	12	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A147	GOTTESMAN	"Bacterial Regulation: Global Regulatory Networks," <i>Ann. Rev. Genet.</i> , 18:415-441 (1984)		
	A148	GRYCZAN	"Molecular Cloning in <i>Bacillus subtilis</i> ," in <i>The Molecular Biology of the Bacilli</i> , edited by Dubnau, Academic Press, New York, Chp. 10:307-329 (1982)		
	A149	GUMBINER	"Proteins Associated with the Cytoplasmic Surface of Adhesion Molecules," <i>Neuron</i> , 11:551-564, October 1993, © Cell Press		
	A150	HAMER et al.	"Regulation <i>In Vivo</i> of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors," <i>J. of Molecular and Applied Genetics</i> , 1:273-288 (1982), © Raven Press, New York		
	A151	HAMMER et al.	"Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human $\beta_2m$ : An Animal Model of HLA-B27-Associated Human Disorders," <i>Cell</i> , 63:1099-1112, November 30, 1990, © Cell Press		
	A152	HERZOG et al.	"Molecular Cloning And Assignment Of FK2, A Novel Human Adhesion Mkinase To 8p11.2-P22 By Nonisotopic In Situ Hybridization," <i>Genomics</i> , 32:484-486 (1996), © Academic Press		
	A153	HILDEBRAND et al.	"Identification of Sequences Required for the Efficient Localization of the Focal Adhesion Kinase, pp125 <sup>FAK</sup> , to Cellular Focal Adhesions," <i>J. Cell. Biology</i> , 123:993-1005 (1993)		
	A154	HILLE	"G Protein-Coupled Mechanisms and Nervous Signaling," <i>Neuron</i> , 9:187-195 (1992), © Cell Press		
	A155	HOUEBINE et al.	"Transgenesis in Fish," <i>Experientia</i> , 47:891-897 (1991), Switzerland		
	A156	HUANG et al.	"Tyrosine Kinase-Dependent Suppression of a Potassium Channel by the G Protein-Coupled m1 Muscarinic Acetylcholine Receptor," <i>Cell</i> , 75:1145-1156 (1993)		
	A157	HURBY et al.	"A User's Guide," <i>Synthetic Peptides</i> , Ed. Grant, Washington University School of Medicine, W.H. Freeman and Company, New York, 289-307 (1992)		
	A158	HUSE et al.	"Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246:1275-1281, December 8, 1989		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	034536-1246
Sheet	13	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A159	HUSTON et al.	"Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity In An Anti-Digoxin Single-Chain Fv Analogue Produced In <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883, August 1988		
	A160	INOUE et al.	"Up-Promotor Mutations In The <i>lpp</i> Gene of <i>Escherichia Coli</i> ," <i>Nucleic Acids Research</i> , 13(9):3100-3111 (1985), © IRL Press Limited, Oxford, England		
	A161	IVERSON and RUDY	"The Role of the Divergent Amino and Carboxyl Domains on the Inactivation Properties of Potassium Channels Derived from the Shaker Gene of <i>Drosophila</i> ," <i>J. Neuroscience</i> , 10(9):2903-2916 (1990)		
	A162	IZAKI	"Plasmid Induced Heavy Metal Resistance," <i>Japanese J. of Bacteriology</i> , 33(6):729-742 (1978)		
	A163	JACKMAN	"ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of L1210 Tumor Cell Growth <i>in Vitro</i> and <i>in Vivo</i> : A New Agent for Clinical Study," <i>Cancer Res.</i> , 51:5579-5586, October 15, 1991		
	A164	JANSEN et al.	"Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <i>Immunological Rev.</i> , 62:185-216 (1982), Munksgaard, Copenhagen, Denmark		
	A165	JOHN et al.	"Plasmids as Epidemiologic Markers in Nosocomial Gram-Negative Bacilli: Experience at a University and Review of the Literature," <i>Reviews of Infectious Diseases</i> , 8(5):693-704, September-October 1986, © The University of Chicago		
	A166	JOHNSON	<i>Proc. Natl. Acad. Sci. US</i> , 90: 5677-5681 (1993)		
	A167	JOHNSON et al.	"Isolation of The Yeast Regulatory Gene GAL4 And Analysis of Its Dosage Effects on The Galactose/Melibiose Regulon," <i>Proc. Natl. Acad. Sci. US</i> , 79: 6971-6975 (1982)		
	A168	JONES et al.	"Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," <i>J. Med. Chem.</i> , 29:1114-1118 (1986), © American Chemical Society		
	A169	JOYNER et al.	"Production of A Mutation In Mouse En-2 Gene By Homologous Recombination In Embryonic Stem Cells," <i>Nature</i> , 338:153-156, March 9, 1989		
	A170	KANEDA et al.	"Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver," <i>Science</i> , 243:375-378, January 20, 1989		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	034536-1246
Sheet	14	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A171	KANEDA et al.	"The Improved Efficient Method for Introducing Macromolecules into Cells Using HVJ (Sendai Virus) Liposomes with Gangliosides," <i>Experimental Cell Res.</i> , 173: 56-69 (1987), © Academic Press, Inc.		
	A172	KASPRZAK et al.	"Location of a Contact Site Between Actin and Myosin in the Three-Dimensional Structure of the Acto-S1 Complex," <i>Biochemistry</i> , 28(23):9230-9238 (1989)		
	A173	KAUR	"Tyrophostin Induced Growth Inhibition: Correlation With Effect on p210 <sup>bcr-abl</sup> Autokinase Activity In K562 Chronic Myelogenous Leukemia," <i>Anti-Cancer Drugs</i> , 5:213-222 (1994), © Rapid Communication of Oxford Ltd.		
	A174	KAWASHIMA et al.	"Genomic Organization Of The Human Homologue Of The Rat Pancreatic Elastase I Gene," <i>DNA Sequence – J. DNA Sequencing and Mapping</i> , 2:303-312 (1992), © Harwood Academic Publishers GmbH, United Kingdom		
	A175	KENDALL et al.	"Plasmid Transfer in Streptomyces lividans: Identification of a kil-kor System Associated with the Transfer Region of PIJ101," <i>J. of Bacteriology</i> , 169(9):4177-4183, September 1987, © American Society for Microbiology		
	A176	KILLEN et al.	"Specific Killing of Lymphocytes that Cause Experimental Autoimmune Myasthenia Gravis by Ricin Toxin-Acetylcholine Receptor Conjugates," <i>J. of Immunology</i> , 133(5):2549-2553, November 1984, © The American Association of Immunologists, USA		
	A177	KING et al.	"Site-Specific Dephosphorylation and Deactivation of the Human Insulin Receptor Tyrosine Kinase By Particular And Soluble Phosphotyrosyl Protein Phosphatases," <i>Biochem. J.</i> , 275:413-418 (1991), Great Britain		
	A178	KÖHLER and MILSTEIN	"Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , 256:495-496, August 7, 1975		
	A179	KOZBOR et al.	"The production of Monoclonal Antibodies from Human Lymphocytes," <i>Immun. Today</i> , 4(3):72-79 (1983), © Elsevier Biomedical Press		
	A180	KUBO et al.	"Cloning, Sequencing and Expression of Complementary DNA Encoding The Muscarinic Acetylcholine Receptor," <i>Nature</i> , 323: 411-416 (1986)		
	A181	KUO et al.	"Effects of Signalling Transduction Modulators on The Transformed Phenotypes In v-H-ras-Transformed NIH 3T3 Cells," <i>Cancer Letters</i> , 74:197-202 (1993), Elsevier Scientific Publishers, Ireland		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	034536-1246
Sheet	15	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A182	LAM et al.	"A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> , 354:82-84, November 7, 1991	
	A183	LAZAR et al.	"Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Mol. And Cell. Biol.</i> , 8(3):1247-1252 (1988), © American Society for Microbiology	
	A184	LEE et al.	"Active-Site-Directed Reductive Alkylation of Xanthine Oxidase by Imidazo[4,5-g]quinazoline-4,9-diones Functionalized with a Leaving Group," <i>Biochemistry</i> , 26(23):7355-7362 (1987), © American Chemical Society	
	A185	LEMUS et al.	"Studies of Extended Quinone Methides, Synthesis and Physical Studies of Purine-Like Monofunctional Imidazo[4,5-g]quinazoline Reductive Alkylating Agents," <i>J. Org. Chem.</i> , 54(15):3611-3618 (1989), © American Chemical Society	
	A186	LEV et al.	"Protein Tyrosine Kinase PYK2 Involved in Ca <sup>2+</sup> -Induced Regulation of ion Channel and MAP Kinase Functions," <i>Nature</i> , 376: 737-745, August 31, 1995	
	A187	LEV et al.	"Interspecies Molecular Chimeras of Kit Help Define the Binding Site of the Stem Cell Factor," <i>Molecular and Cellular Biology</i> , 13(4):2224-2234, April 1993, © American Society for Microbiology	
	A188	LEVITZKI	"Tyrophostins: Tyrosine Kinase Blockers As Novel Antiproliferative Agents and Dissectors of Signal Transduction," <i>FASEB J.</i> , 6:3275-3282, November 1992	
	A189	LEY et al.	"Synthesen Unter Verwendung von Benzofuroxan," <i>Synthesis</i> , 1975:415-422, July 1975	
	A190	LIU et al.	"Regulation of c-Src tyrosine Kinase Activity by the Src SH2 Domain," <i>Oncogene</i> , 8:1119-1126 (1993), © Macmillan Press Ltd.	
	A191	LOGAN et al.	"Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection," <i>Proc. Natl. Acad. Sci. USA</i> , 81:3655-3659, June 1984	
	A192	LOPEZ et al.	<u>Journal of Clinical Investigation</u> , August 1997, pp. 664-670, Vol. 100, No. 3	
	A193	LOWY et al.	"Isolation of Transforming DNA: Cloning the Hamster apt Gene," <i>Cell</i> , 22:817-823 December 1980, © MIT	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Attorney Docket Number	034536-1246				
Sheet	16	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A194	LUTZ et al.	"The Distribution of Two hnRNP-Associated Proteins Defined by a Monoclonal Antibody Is Altered in Heat-Shocked HeLa Cells," <i>Experimental Cell Res.</i> , 175:109-124 (1988), © Academic Press, Inc.	
	A195	LYALL et al.	"Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <i>J. Bio. Chem.</i> , 264(24):14503-14509, August 25, 1989, © American Society for Biochemistry and Molecular Biology, Inc., USA	
	A196	MAGUIRE et al.	"A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," <i>J. Med. Chem.</i> , 37(14):2129-2137 (1994), © American Chemical Society	
	A197	MANIATIS	"Study of Eukaryotic Genes: Recombinant DNA Procedures," <i>Cell Biology: A Comprehensive Treatise, Volume 3, Gene Sequence Expression</i> , Academic Press, NY, Chp. 11: 563-608 (1980)	
	A198	MANSER et al.	"A Non-Receptor Tyrosine Kinase That Inhibits the GTPase Activity of p21 <sup>cdc42</sup> ," <i>Nature</i> , 363:364-367 (1993)	
	A199	MARASCO et al.	"Design, Intracellular Expression, and Activity of a Human Anti-Human Immunodeficiency Virus Type 1 gp 120 Single-Chain Antibody," <i>Proc. Natl. Acad. Sci. USA</i> , 90:7889-7893, August 1993	
	A200	MAXWELL et al.	" <sup>19</sup> F Nuclear Magnetic Resonance Imaging of Drug Distribution <i>in Vivo</i> : The Disposition of an Antifolate Anticancer Drug in Mice," <i>Magnetic Resonance in Medicine</i> , 17:189-196 (1991), © Academic Press, Inc.	
	A201	MCKNIGHT	"Functional Relationships Between Transcriptional Control Signals of the Thymidine Kinase Gene of Herpes Simplex Virus," <i>Cell</i> , 31:355-365, December 1982 (Part 1), © MIT	
	A202	McLEAN et al.	"Oxcarbazepine: Mechanisms of Action," <i>Epilepsia</i> , 35(3):55-59 (1994), Raven Press, New York	
	A203	MILLAUER et al.	"Glioblastoma Growth Inhibited <i>in vivo</i> By a Dominant-Negative Flk-1 Mutant," <i>Nature</i> , 367:576-579, February 10, 1994	
	A204	MILLER	"Human Gene Therapy Comes of Age," <i>Nature</i> , 357:455-460, June 11, 1992	
	A205	MILLER et al.	"Improved Retroviral Vectors for Gene Transfer and Expression," <i>Biotechniques</i> , 7(9):982-988 (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Prior Application Number</b>	09/476,484
				<b>Prior Appl. Filing Date</b>	12/30/99
				<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	17	of	24	<b>Attorney Docket Number</b>	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
-	A206	MILLER et al.	"An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes," in <i>Genetic Engineering: Principles and Methods</i> , Eds. Setlow et al., Plenum Press, New York 8:277-298 (1986)		
-	A207	MINI et al.	"Cytotoxic Effects of Folate Antagonists against Methotrexate-resistant Human Leukemic Lymphoblast CCRF-CEM Cell Lines," <i>Cancer Res.</i> , 45:325-330, January 1985		
-	A208	MIYACHI et al.	"Use of Copper(I) Trifluoromethanesulfonate in $\beta$ -Lactam Synthesis," <i>J. Org. Chem.</i> , 54(15):3511-3513, July 21, 1989, © American Chemical Society		
-	A209	MORRISON et al.	"Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81:6851-6855, November 1984		
	A210	MULLIGAN	"The Basic Science of Gene Therapy," <i>Science</i> , 260: 926-932, May 14, 1993		
	A211	MULLIGAN et al.	"Selection For animal Cells That Express the Escherichia Coli Gene Coding For Xanthine-Guanine Phosphoribosyltransferase," <i>PNAS</i> , 78(4):2072-2076, April 1981		
	A212	MURPHY et al.	"Neuronal Selectivity of ATP-Sensitive Potassium Channels in Guinea-Pig Substantia Nigra Revealed By Responses To Anoxia," <i>J. of Physiology</i> , 453:167-183 (1992), Great Britain		
	A213	MURPHY et al.	"ATP-Sensitive Potassium Channels Counteract Anoxia in Neurons of the Substantia niagra," <i>Exp. Brain Res.</i> , 84:355-358 (1991), © Springer Verlag		
	A214	NADA et al.	"Cloning of a Complementary DNA for a Protein-Tyrosine Kinase that Specifically Phosphorylates a Negative Regulatory Site of p60 <sup>c-src</sup> ," <i>Nature</i> , 351:69-72, May 2, 1991		
	A215	NASANOVA et al.	"Mixed Connective Tissue Disease," <i>Ter Arkh</i> , 1982, pp. 12-19, Vol. 54, No. 6 (abstract, English only)		
	A216	NELSON	"Detection of Acridinium Esters by Chemiluminescence," <i>Nonisotopic DNA Probe Techniques</i> , Ed. Larry J. Kricka, Academic Press, San Diego, Chapter 12, 275-310 (1992)		
	A217	NEUBERGER et al.	"Recombinant Antibodies Possession Novel Effector Functions," <i>Nature</i> , 312:604-608, December 13, 1984		

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	18	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A218	O'HARE et al.	"Transformation of mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing A Prokaryotic Dihydrofolate Reductase," <i>PNAS</i> , 78(3):1527-1531, March 1981		
	A219	OKAYAMA et al.	"A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <i>Molecular and Cellular Biology</i> , 3(2):280-289, February 1983, © American Society for Microbiology		
	A220	OLPE et al.	"4-Aminopyridine and Barium Chloride Attenuate the Anti-Epileptic Effect of Carbamazepine in Hippocampal Slices," <i>Experientia</i> , 47:254-257 (1991), Birkhauser Verlag, Basel, Switzerland		
	A221	PETERSON and BARNES	"Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells But Not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <i>The Prostate</i> , 22: 335-345 (1993), © Wiley-Liss, Inc.		
	A222	PHILLIPS et al.	"Quino[1,2-c]quinazolinines.I.Synthesis of Quino[1,2-c]quinazolinium Derivatives and the Related Indazolo[2,3-a]quinoline Derivatives As Analogs of the Antitumor Benzo[c]phenanthridine Alkaloids," <i>J. Heterocyclic Chemistr</i> , 17:1489-1496, November 1980, © HeteroCorporation		
	A223	PILLEMER et al.	"Insulin Dependence of Murine Lymphoid T-Cell Leukemia," <i>J. Cancer</i> , 50:80-85 (1992), © Wiley-Liss, Inc.		
	A224	POPOLI et al.	"Cromakalim (BRL 34915) Counteracts the Epileptiform Activity Elicited By Diltiazem and Verapamil in Rats," <i>Br. J. Pharmacol</i> , 104:907-913 (1991), © Macmillan Press Ltd.		
	A225	PORTER et al.	"New Antiepileptic Drugs: From Serendipity to Rational Discovery," <i>Epilepsia</i> , 33(1):S1-S6 (1992), Raven Press Ltd., New York		
	A226	POSNER et al.	"Kinetics of Inhibition by Tyrphostins of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Analysis by a New Computer Program," <i>Molecular Pharmacology</i> , 45:673-683 (1993), © The American Society for Pharmacology and Experimental Therapeutics		
	A227	PURSEL et al.	"Genetic Engineering of Livestock," <i>Science</i> , 244:1281-1288, June 16, 1989		
	A228	REECE et al.	"Pharmacokinetics of Trimetrexate Administered by Five-Day Continuous Infusion to Patients with Advanced Cancer," <i>Cancer Res.</i> , 47:2996-2999, June 1, 1987		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	19	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
-	A229	RENDU et al.	"Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <i>Biochem. Pharm.</i> , 44(5):881-888 (1992), © Pergamon Press Ltd., Great Britain		
-	A230	RICARD-MOUSNIER et al.	"Involvement of Voltage-Dependent Ion Channels in Epileptogenesis," <i>Neurophysiol Clin</i> , 23:395-421 (1993), © Elsevier, Paris		
-	A231	RIDLEY et al.	"The Small GTP-Binding Protein rho Regulates the Assembly of Focal Adhesions and Actin Stress Fibers in Response to Growth Factors," <i>Cell</i> , 70:389-399, August 7, 1992, © Cell Press		
-	A232	RODRIGUEZ-PENA et al.	"Rapid Dephosphorylation of a Mr 80000 Protein, a Specific Substrate of Protein Kinase C Upon removal of Phorbol Esters, Bombesin and Vasopressin," <i>Biochemical and Biophysical Comm.</i> , 140(1):379-385, October 15, 1996		
	A233	ROTIN et al.	"SH2 Domains Prevent Tyrosin Dephosphorylation fo The EGF Receptor: Identification of Tyr992 as The High-Affinity Binding Site for SH2 Domains of Phospholipase C $\gamma$ " <i>EMBO J.</i> , 11(2):559-567 (1992), © Oxford University Press		
	A234	RUBIN	"Drosophila Melanogaster As An Experimental Organism," <i>Science</i> , 240:1453-1459, June 10, 1988		
	A235	RUTHER et al.	"Easy Identification of cDNA Clones," <i>EMBO J.</i> , 2(10):1791-1794 (1983)		
	A236	SADOSHIMA et al.	"The heterotrimeric G $\alpha$ Protein-Coupled Angiotensin II Receptor Activates p21 <sup>ras</sup> Via the Tyrosine Kinase-Shc-Grb2-Sos Pathway in Cardian Myocytes," <i>EMBO J.</i> , 15(4):775-787 (1996)		
	A237	SANTERRE et al.	"Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance As Dominant-Selection Markers in Mouse L Cells," <i>Gene</i> , 30:147-156 (1984), Elsevier		
	A238	SASAKI et al.	"Cloning of a cDNA for the Human Adhesion Kinase Beta," <i>Tumor Res.</i> , 30:37-46 (1995)		
	A239	SAURO et al.	"Decreased Sensitivity of Aorta from Hypertensive Rats to Vasorelaxation by Tyrphostin," <i>Life Sciences</i> , 53(22):371-376 (1993), Pergamon Press, USA		
	A240	SAURO et al.	"Tyrphostin Attenuates Platelet-Derived Growth Factor-Induced Contraction in Aortic Smooth Muscle Through Inhibition of Protein Tyrosine Kinase(s)," <i>J. of Pharmacology and Experimental Therapeutics</i> , 267(3):1119-1125 (1993), © The American Society for Pharmacology and Experimental Therapeutics, USA		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	20	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A241	SCHALLER et al.	"Focal Adhesion Kinase: an Integrin-Linked Protein Tyrosine Kinase,"		
	A242	SCHALLER et al.	"Autonomous Expression of a Noncatalytic Domain of the Focal Adhesion-Associated Protein Tyrosine Kinase pp125 <sup>FAK</sup> ," <i>Mol. and Cell. Biol.</i> , 13(2):785-791, February 1993, © American Society for Microbiology		
	A243	SCHALLER et al.	"pp125 <sup>FAK</sup> , a Structurally Distinctive Protein-Tyrosine Kinase Associated with Focal Adhesions," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5192-5196, June 1992		
	A244	SCHLESSINGER	"Signal Transduction by Allosteric Receptor Oligomerization," <i>Trends in Biochemical Sciences</i> , 13:443-447, November 1988, The International Union of Biochemistry and Elsevier Publications Cambridge		
	A245	SCHREY et al.	"Bombesin and Glucocorticoids Stimulate Human Breast Cancer Cells to Produce Endohelin, a Paracrine Mitogen for Breast Stromal Cells," <i>Cancer Res.</i> , 52:1786-1790, April 1, 1992		
	A246	SCULIER et al.	"Role of an Intensive Care Unit (ICU) In a Medical Oncology Department," <i>Cancer Immunol. and Immunotherapy</i> , 23:A65 (1986)		
	A247	SHATTIL et al.	"Tyrosine Phosphorylation of pp125 <sup>FAK</sup> in Platelets Requires Coordinated Signalling Through Integrin and Agonist Receptors," <i>J. Biol. Chem.</i> , 269(2):14738-14745, May 20, 1994, © The American Society for Biochemistry and Molecular Biology, Inc., USA		
	A248	SIKORA et al.	"Development of an Assay for the Estimation of N <sup>10</sup> -Propargyl-5,8-dideazafolic Acid Polyglutamates in Tumor Cells," <i>Analytical Biochemistry</i> , 172:344-355 (1988), © Academic Press		
	A249	SIKORA et al.	"Quinazoline CB 3717 and CB 3703 Inhibitors of Folate Retention and Metabolism in Ehrlich Ascites Carcinoma Cells and Some Organs of the Host-Mouse," <i>Cancer Letters</i> , 23:289-295 (1984), Elsevier Scientific Publishers Ireland Ltd.		
	A250	SILVER et al.	"Amino Terminus of the Yeast GAL4 Gene Product is Sufficient for Nuclear Localization," <i>Proc. Natl. Acad. Sci. USA</i> , 81:5951-5955, October 1984		
	A251	SIMON et al.	"Potassium Channel Openers Block Seizure Activity In an <i>In-Vitro</i> Model of Epilepsy," <i>Biophys. J.</i> , 64:A100 (1993)		
	A252	SIMONS et al.	"Gene Transfer into Sheep," <i>Bio/Technology</i> , 6:179-182, February 1988		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1246
Sheet	21	of	24		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
-	A253	SKOLNIK et al.	"Cloning of P13 Kinase-Associated p85 Utilizing a Novel Method for Expression/Cloning of Target Proteins for Receptor Tyrosin Kinases," <i>Cell</i> , 65:83-90, April 5, 1991, © Cell Press		
-	A254	SMITH et al.	"Single-Step Purification of Polypeptides Expressed in <i>Escherichia coli</i> as Fusions with Glutathione S-Transferase," <i>Gene</i> , 67:31-40 (1988)		
-	A255	SMITH et al.	"Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the Polyhedrin Gene," <i>J. Virology</i> , 46(2):584-593, May 1983, © May 1983		
-	A256	SONGYANG et al.	"SH2 Domains Recognize Specific Phosphopeptide Sequences," <i>Cell</i> , 72:767-778, March 12, 1993, © Cell Press		
-	A257	ST. GROTH et al.	"Production of Monoclonal Antibodies: Strategy and Tactics," <i>J. Immunol. Methods</i> , 35:1-21 (1980), © Elsevier/North-Holland Biomedical Press		
-	A258	STERNBERGER et al.	"The Unlabeled Antibody Enzyme Method of Immunohistochemistry: Preparation and Properties of Soluble Antigen-Antibody Complex (Horseradish Peroxidase-Antihorseradish Peroxidase) and its Use in Identification of Spirochetes," <i>J. Histochemistry and Cytochemistry</i> , 18(5):315-333 (1970), © The Histochemical Society, Inc., USA		
-	A259	SU	"Delineating Biochemical and Functional Properties of Sigma Receptors: Emerging Concepts," <i>Critical Reviews in Neurobiology</i> , 7(3,4):187-203 (1993), © CRC Press, Inc.		
-	A260	SURWIT et al.	<u>Arch Dermatol.</u> , March 1984, pp. 329-331, Vol. 120		
-	A261	SZYBALSKA et al.	"Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>PNAS</i> , 48:2026-2034 (1962)		
-	A262	TAKEDA et al.	"Construction of Chimaeric Processed Immunoglobulin Genes Containing mouse Variable and Human Constant Region Sequences," <i>Nature</i> , 314:452-454, April 4, 1985		
-	A263	TAO et al.	"Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG constant Region" <i>J. Immunol.</i> , 143(8):2595-2601, October 15, 1989, © The American Association of Immunologists, USA		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/476,484
				Prior Appl. Filing Date	12/30/99
				First Named Inventor	Joseph SCHLESSINGER et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	22	of	24	Attorney Docket Number	034536-1246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A264	TIJSSEN	"Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology," Volume 15, Elsevier Science Publishers, Amsterdam, The Netherlands, (TABLE OF CONTENTS ONLY) (1985)		
	A265	TOKIWA et al.	"Activation of Pyk2 by Stress Signals and Coupling with JNK Signaling Pathway," <i>Science</i> , 273:792-794, August 9, 1996		
	A266	TREHERNE et al.	"The Regional Distribution of Sulphonylurea Binding Sites in Rat Brain," <i>Neuroscience</i> , 40(2):523-531 (1991), © Pergamon Press plc, Great Britain		
	A267	ULLRICH et al.	"Signal Transduction by Receptors with Tyrosine Kinase Activity," <i>Cell</i> , 61:203-212, April 1990, © Cell Press		
	A268	ULMANEN et al.	"Transcription and Translation of Foreign Genes in <i>Bacillus subtilis</i> by the Aid of a Secretion Vector," <i>J. Bacteriology</i> 162(1):176-182, April 1985, © American Society for Microbiology		
	A269	van BIESEN et al.	"Receptor-Tyrosine-Kinase- and G $\beta$ -Mediated MAP Kinase Activation by a Common Signaling Pathway," <i>Nature</i> , 376:781-784, August 31, 1995		
	A270	VAN HEEKE et al.	"Expression of Human Asparagine Synthetase in <i>Escherichia Coli</i> ," <i>J. Biol. Chem.</i> , 264(10):5503-5509, April 5, 1989, © The American Society for Biochemistry and Molecular Biology, Inc., USA		
	A271	WAN et al.	"Tyrosine Kinases in Activation of the MAP Kinase Cascade by G-Protein-Coupled Receptors," <i>Nature</i> , 380:541-544, April 11, 1996		
	A272	WARD et al.	"Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546, October 12, 1989		
	A273	WARD et al.	"Construction and Characterisation of a Series of Multi-Copy Promoter-Probe Plasmid Vectors for <i>Streptomyces</i> Using the Aminoglycoside Phosphotransferase Gene from Tn5 as Indicator," <i>Mol. Gen. Genet.</i> , 203:468-478 (1986), © Springer-Verlag		
	A274	WHITNEY et al.	"Human T and B Lymphocytes Express a Structurally Conserved Focal Adhesion Kinase pp125 <sup>FAK</sup> ," <i>DNA Cell Biol.</i> , 12(9):823-830 (1993), Mary Ann Liebert, Inc., Publishers		
	A275	WIGLER et al.	"Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," <i>Cell</i> , 11:223-232, May 1977, © MIT		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Prior Application Number</b>	09/476,484
		<b>Prior Appl. Filing Date</b>	12/30/99
		<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-1246
Sheet	23	of	24

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A276	WIGLER et al.	"Transformation of Mammalian Cells with an Emplifiable Dominant-Acting Gene," <i>Proc. Natl. Acad. Sci. USA</i> , 77(6):3567-3570, June 1980	
	A277	WIGLER et al.	"Transformation of Mammalian Cells with Genes from Procaryotes and Eucaryotes," <i>Cell</i> , 16:777-785, April 1979, © MIT	
	A278	WILCHEK et al.	"The Literature on Affinity Chromatography," <i>Methods in Enzymology</i> , 34:3-10 (1974)	
	A279	WILK-BLASZCZAK et al.	"Bradykinin Modulates Potassium and Calcium Currents in Neuroblastoma Hybrid Cells via Different Pertussis Toxin-Insensitive Pathways," <i>Neuron</i> , 12:109-116, January 1994, © Cell Press	
	A280	WILSON et al.	"Clinical Protocol: <i>Ex Vivo</i> Gene Therapy of Familial Hypercholesterolemia," <i>Human Gene Therapy</i> , 3:179-222 (1991), Mary Ann Liebert, Inc., Publishers	
	A281	WILSON et al.	"Distribution and Molecular Characterization of a Cell-Surface and a Cytoplasmic Antigen Detectable in Human Melanoma Cells with Monoclonal Antibodies," <i>Int. J. Cancer</i> , 28:293-300 (1981)	
	A282	WOLBRING et al.	"Inhibition of GTP-Utilizing Enzymes by Tyrphostins," <i>J. Biol. Chem.</i> , 269(36):22470-22472 (1994), © The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A283	WOLFF et al.	"Direct Gene Transfer into Mouse Muscle <i>In Vivo</i> ," <i>Science</i> , 247: 1465-1468 (1990)	
	A284	WU et al.	"Receptor-Mediated <i>In Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <i>J. Biol. Chem.</i> , 262(10):4429-4432, April 5, 1987, © The American Society of Biological Chemists, Inc., USA	
	A285	WU et al.	"Receptor-Mediated Gene Delivery <i>In Vivo</i> , Partial Correction of Genetic Analbuminemia in NagasRats," <i>J. Biol. Chem.</i> , 266:14338-14342, August 5, 1991, © The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A286	XIE et al.	"Dominant-Negative Mutants of Grb2 Induced Reversal of the Transformed Phenotypes Caused by The Point Mutation-Activated Rat HER-2/Neu," <i>J. Biol. Chem.</i> , 270(51):30717-30724, December 22, 1995, © The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A287	YANG et al.	"Human Very Low Density Lipoprotein Structure: Interaction of the c Apolipoproteins With Apolipoprotein B-100," <i>J. Lipid Research</i> , 34(8):1311-1321, August 1993	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449B/PTO

**Complete if Known**

*(use as many sheets as necessary)*

<b>Prior Application Number</b>	09/476,484
<b>Prior Appl. Filing Date</b>	12/30/99
<b>First Named Inventor</b>	Joseph SCHLESSINGER et al.
<b>Group Art Unit</b>	Unassigned
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	034536-1246

Sheet	24	of	24
-------	----	----	----

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

**Examiner  
Signature**

Date Considered

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.